Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Population pharmacokinetic rationale for intravenous contezolid acefosamil followed by oral contezolid dosage regimens.
Journal: Antimicrobial agents and chemotherapy
Published: February 28, 2024
Clinical Response of Tedizolid versus Linezolid in Acute Bacterial Skin and Skin Structure Infections by Severity Measure Using a Pooled Analysis from Two Phase 3 Double-Blind Trials.
Journal: Antimicrobial agents and chemotherapy
Published: January 04, 2017
Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
Journal: American journal of therapeutics
Published: December 13, 2016
Efficacy, safety, tolerability and population pharmacokinetics of tedizolid, a novel antibiotic, in Latino patients with acute bacterial skin and skin structure infections.
Journal: The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases
Published: December 01, 2015
Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.
Journal: International journal of antimicrobial agents
Published: July 08, 2015
Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
Journal: Antimicrobial agents and chemotherapy
Published: November 26, 2014
Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials.
Journal: Antimicrobial agents and chemotherapy
Published: September 24, 2014
Pharmacokinetics of tedizolid in subjects with renal or hepatic impairment.
Journal: Antimicrobial agents and chemotherapy
Published: August 20, 2014
Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
Journal: Pharmacotherapy
Published: July 04, 2014
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
Journal: The Lancet. Infectious diseases
Published: June 10, 2014
Absorption, distribution, metabolism, and excretion of the novel antibacterial prodrug tedizolid phosphate.
Journal: Drug metabolism and disposition: the biological fate of chemicals
Published: May 31, 2014
Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 18, 2013
Last Updated: 09/26/2026